Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
Instituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín, CP 1650 San Martín, Argentina; Department of Health Technology, Technical University of Denmark, DK-2800 Lyngby, Denmark.
Hum Immunol. 2023 Nov;84(11):578-589. doi: 10.1016/j.humimm.2023.08.145. Epub 2023 Sep 9.
The Cancer Epitope Database and Analysis Resource (CEDAR) is a newly developed repository of cancer epitope data from peer-reviewed publications, which includes epitope-specific T cell, antibody, and MHC ligand assays. Here we focus on prostate cancer as our first cancer category to demonstrate the capabilities of CEDAR, and to shed light on the advances of epitope-related prostate cancer research.
The meta-analysis focused on a subset of data describing epitopes from 8 prostate-specific (PS) antigens. A total of 460 epitopes were associated with these proteins, 187 T cell, 109B cell, and 271 MHC ligand epitopes. The number of epitopes was not correlated with the length of the protein; however, we found a significant positive correlation between the number of references per specific PS antigen and the number of reported epitopes. Forty-four different class I and 27 class II restrictions were found, with the most epitopes described for HLA-A02:01 and HLA-DRB101:01. Cytokine assays were mostly limited to IFNg assays and a very limited number of tetramer assays were performed. Monoclonal and polyclonal B cell responses were balanced, with the highest number of epitopes studied in ELISA/Western blot assays. Additionally, epitopes were generically described as associated with prostate cancer, with little granularity specifying diseases state. We found that in vivo and tumor recognition assays were sparse, and the number of epitopes with annotated B/T cell receptor information were limited. Potential immunodominant regions were identified by the use of the ImmunomeBrowser tool.
CEDAR provides a comprehensive repository of epitopes related to prostate-specific antigens. This inventory of epitope data with its wealth of searchable T cell, B cell and MHC ligand information provides a useful tool for the scientific community. At the same time, we identify significant knowledge gaps that could be addressed by experimental analysis.
癌症抗原数据库和分析资源 (CEDAR) 是一个新开发的癌症抗原数据存储库,来源于同行评议的出版物,其中包括抗原特异性 T 细胞、抗体和 MHC 配体检测。在这里,我们以前列腺癌作为第一个癌症类别,展示 CEDAR 的功能,并揭示与抗原相关的前列腺癌研究的进展。
该荟萃分析集中于描述 8 种前列腺特异性 (PS) 抗原的抗原数据子集。共有 460 个与这些蛋白相关的抗原,其中 187 个是 T 细胞抗原,109 个是 B 细胞抗原,271 个是 MHC 配体抗原。抗原数量与蛋白长度无关;然而,我们发现每个特定 PS 抗原的参考文献数量与报告的抗原数量之间存在显著的正相关。发现了 44 种不同的 I 类和 27 种 II 类限制,其中描述最多的抗原是 HLA-A02:01 和 HLA-DRB101:01。细胞因子检测大多限于 IFNg 检测,仅进行了非常有限的四聚体检测。单克隆和多克隆 B 细胞反应平衡,在 ELISA/Western blot 检测中研究最多的抗原。此外,抗原被笼统地描述为与前列腺癌相关,很少有明确的疾病状态特异性。我们发现体内和肿瘤识别检测很少,具有注释 B/T 细胞受体信息的抗原数量有限。使用 ImmunomeBrowser 工具确定了潜在的免疫优势区域。
CEDAR 提供了一个与前列腺特异性抗原相关的抗原的全面存储库。这些丰富的可搜索 T 细胞、B 细胞和 MHC 配体信息的抗原数据为科学界提供了一个有用的工具。同时,我们也发现了一些重大的知识空白,这些空白可以通过实验分析来解决。